11 DECEMBER 1971 abnormal platelet function. This is unlikely to be a significant factor in the series because of the different pattern of abnormality (Marcus, 1969) and the presence of abnormal function in patients who had not taken aspirin.
The higher platelet count and normal platelet function found in six patients studied in convalescence suggests that abnormal platelet function may reflect a platelet lesion predisposing to platelet destruction. Megakaryocyte hyperplasia in bone marrow smears from patients with uncomplicated infectious mononucleosis and mild thrombocytopenia (Boyd and Reid, 1968) supports the concept that platelet destruction determines thrombocytopenia in infectious mononucleosis. As thrombocytopenia occurs in about half of the patients with infectious mononucleosis at some stage of disease (Carter, 1965; Cantow and Kostinas, 1966) , increased platelet removal would occur in most patients. That intracorpuscular lesions can determine premature platelet destruction has been well established (Murphy et al., 1969) .
The relationship of abnormal platelet function to the rare complication of thrombocytopenic purpura is less clear. In several patients studied with thrombocytopenia complicating specific viral infections, very short isologous platelet survival indicated an antiplatelet factor. One of these patients had transient abnormalities of platelet function on recovery , suggesting a possible link with the more common asymptomatic form of thrombocytopenia. However, because of the rarity of thrombocytopenic purpura, other mechanisms could be involved in determining very low platelet counts. A second consequence of abnormal platelet function is impaired haemostasis, and such defects may account for the purpura occasionally seen in patients with only mild to moderate thrombocytopenia in infectious mononucleosis (Schumacher and Barcay, 1962) .
The role of abnormal platelet function in determining the outcome of virus-platelet interaction in other infections is not known. It is of interest, however, that a patient with rubella had similar platelet abnormalities and an added defect induced by virus infection may lead to an exacerbation of purpura.
Introduction
We have previously reported that blood clotting tests, including specific factor VII and X assays, became accelerated in women taking conventional oestrogen/progestogen oral contraceptives (Thomson and Poller, 1965; Poller and Thomson, 1966) . These changes became significant from the third cycle of administration. When two oral contraceptives of varying hormone content -that is, Norinyl-1 and Ortho-Novin-were compared it seemed that the changes in clotting factor response were similar during the first nine months covered by our report (Poller et al., 1968) . We stated, however, that longer study was required to eliminate the possibility of gradual cumulative effects.
The present study is a follow-up of the same two groups of women taking the two preparations and extends to four years with Norinyl-1 and to the third year with Ortho-Novin. The use of the latter was discontinued prematurely after the report by the Committee on Safety of Drugs (Inman et al., 1970) .
Method of Study Follow-up clotting studies at intervals of six months were continued in 26 women taking Norinyl-1 and 21 women taking Ortho-Novin. Laboratory technique was as previously described (Poller et al., 1968) with the addition of thrombelastography, "r" (reaction time), "k" (thrombin time), and "ma" (maximum amplitude) being recorded. Platelet aggregation studies with Chandler's tube (Poller et al., 1969) were also made between the second and fourth years of the study. Each woman taking a "pill" preparation was compared with a parallel control. This was to avoid variables which occur in coagulation assays in a long-term study due to alterations in reagents etc. Follow-up was continued with Norinyl-1 until the four-year stage, but during the third year of the study all the Ortho-Novin women were changed to the lower-dose oestrogen preparation, Norinyl-1. This contains half the hormone content of Ortho-Novin and only 0-05 mg of oestrogen, which is acceptable (Inman et al., 1970) . From this time the Ortho-Novin women were excluded from the trial.
Results of blood clotting tests, given in Table I , were analysed, the paired t test being used. The women were contrasted with parallel normals at each stage in order to overcome the variables in coagulation assays in a long-term study. The thrombelastogram is not affected by such variables. The results of thrombelastography were therefore analysed on a group basis. The same analysis was applied to the Chandler's tube results as there was no continuous follow-up.
Results
Of 26 women on Norinyl-1 at the nine-month stage included in this study, 19 remained at four years. Of 21 women taking Ortho-Novin, 17 remained in the third year. The prothrombin times were significantly accelerated throughout in both groups. Cephalin times and kaolin-activated cephalin times were accelerated up to the two-year stage in both groups and also during the fourth year.
Factor VII and X assays, which were significantly accelerated in both pill groups at the nine-month stage, remained accelerated throughout the four-year period of follow-up (see Table I ). There was nothing to suggest a cumulative effect on factor VII or X levels during the same period. Five women with a very pronounced degree of acceleration of these clotting factors and a very abnormal thrombelastographic pattern in the third and fourth years were, however, advised to discontinue. The results were therefore subject to a degree of bias towards hypocoagulability in the later stages of the trial.
Thrombelastography.-A normal thrombelastographic pattern is given in the Figure (A) , and is compared with the typical pattern produced during oral contraceptive administration (B). The three criteria measured, r, k, and ma, are illustrated.
Detailed results are given in Table II . There was a shortening of the r time throughout both Ortho-Novin and Norinyl-1 administration, whereas the k value became significantly shortened in both these groups only from the 30th month. The ma value was not significantly increased though 12-6% of the thrombelastographic patterns did show a pronounced increase 19- in ma value during this study. The increases in r and k were progressive during the four years.
Platelet Aggregation.-The platelet aggregation time measured by Chandler's tube at the three-year stage and subsequently was significantly shortened (see Table III ). Comment Long-term follow-up of women taking conventional combined oral contraceptive preparations-Ortho-Novin and Norinyl-lindicates that the significant rises in clotting factors VII and X which had appeared at the three-month stage persisted. These changes do not seem to be cumulative though the smaller numbers at later stages make the assessment difficult. The group of women who were excluded in the later stages because of accelerated blood clotting also complicated the assessment of a cumulative effect. Their exclusion led to bias in the results and may also explain why the shortening of the cephalin times was not significant during the third year. One of the two preparations studied-that is, Ortho-Novinis now no longer on the approved list of preparations as it contains more than the recommended 50 ,ug of oestrogen, being in the "higher thromboembolic risk" group (Inman et al., 1970) . There is no firm evidence, from long-term administration in this study, that the clotting factor response is dose-dependent. Similar findings were reported previously at the nine-month stage (Poller et al., 1968) .
The pronounced acceleration of platelet aggregation in Chandler's tube at the third-year and fourth-year stages is of interest. We have previously shown that this test is accelerated in women taking combined oral contraceptives, during normal pregnancy (Poller et al., 1969) , and when the intrinsic clotting system is accelerated during physiological exercise (Poller et al., 1971) . The thrombelastographic pattern with oral contraception seems to be different from changes in other so-called "prethrombotic" states. The r time, thought to represent the formation of the intrinsic prothrombin-converting principle, was accelerated throughout in both groups. In contrast the ma value for the oral contraceptive groups was at no time significantly increased, unlike the changes in patients with thrombosis, after exercise, and during pregnancy. Some women in this study did in fact show a pronounced change in ma value though this was not sufficient to produce a significant increase for the entire group. A progressive shortening of k value arose during the study, which may suggest some cumulative effect in intrinsic clotting. The thrombelastographic changes therefore seem to support the data from Chandler's tube test, indicating accelerated clotting.
The evidence from a long-term study of a continued acceleration of clotting tests therefore reflects changes in both intrinsic and extrinsic clotting induced by oestrogen/progestogen oral contraception. None of our patients suffered from thrombosis clinically but this trial was intended only to monitor the clotting changes in a small population of healthy normal women and not to provide data on the incidence of thrombosis.
